All Stories

  1. HPV Testing Versus Cytology for Cervical Cancer Screening Among Women 50 Years and Older: Evidence From the HPV FOCAL Randomized Controlled Trial
  2. Diversity, equity, and inclusion as scientific rigor: progress during challenging times
  3. Diversity, equity, and inclusion as scientific rigor: progress during challenging times
  4. Time to diagnosis among children and adolescents with cancer in Quebec, Canada: a population-based study
  5. Recurrent Cervical HPV16 DNA Detection in Unvaccinated Women According to Presumed HPV16 Exposure Based on IgG and IgM Seroreactivity
  6. Pre-school or infant HPV immunization?
  7. Data from A Review of Ethical and Legal Aspects of Gender-Neutral Human Papillomavirus Vaccination
  8. Data from Clinical Performance of the BD Onclarity Extended Genotyping Assay for the Management of Women Positive for Human Papillomavirus in Cervical Cancer Screening
  9. Data from Ecologic Analysis of Correlates of Cervical Cancer Morbidity and Mortality in Sub-Saharan Africa
  10. Supplementary Figure 1 from Site-Specific Cancer Incidence by Race and Immigration Status in Canada 2006–2015: A Population-Based Data Linkage Study
  11. Supplementary Figure from A Review of Ethical and Legal Aspects of Gender-Neutral Human Papillomavirus Vaccination
  12. Supplementary Figure from Clinical Performance of the BD Onclarity Extended Genotyping Assay for the Management of Women Positive for Human Papillomavirus in Cervical Cancer Screening
  13. Supplementary Figure from Ecologic Analysis of Correlates of Cervical Cancer Morbidity and Mortality in Sub-Saharan Africa
  14. Supplementary Table 1 from Site-Specific Cancer Incidence by Race and Immigration Status in Canada 2006–2015: A Population-Based Data Linkage Study
  15. Supplementary Table 2 from Site-Specific Cancer Incidence by Race and Immigration Status in Canada 2006–2015: A Population-Based Data Linkage Study
  16. Supplementary Table 3 from Site-Specific Cancer Incidence by Race and Immigration Status in Canada 2006–2015: A Population-Based Data Linkage Study
  17. Supplementary Table 4 from Site-Specific Cancer Incidence by Race and Immigration Status in Canada 2006–2015: A Population-Based Data Linkage Study
  18. Supplementary Table from A Review of Ethical and Legal Aspects of Gender-Neutral Human Papillomavirus Vaccination
  19. Supplementary Table from A Review of Ethical and Legal Aspects of Gender-Neutral Human Papillomavirus Vaccination
  20. Supplementary Table from A Review of Ethical and Legal Aspects of Gender-Neutral Human Papillomavirus Vaccination
  21. Supplementary Table from A Review of Ethical and Legal Aspects of Gender-Neutral Human Papillomavirus Vaccination
  22. Supplementary Table from A Review of Ethical and Legal Aspects of Gender-Neutral Human Papillomavirus Vaccination
  23. Supplementary Table from A Review of Ethical and Legal Aspects of Gender-Neutral Human Papillomavirus Vaccination
  24. Supplementary Table from Ecologic Analysis of Correlates of Cervical Cancer Morbidity and Mortality in Sub-Saharan Africa
  25. Supplementary Table from Ecologic Analysis of Correlates of Cervical Cancer Morbidity and Mortality in Sub-Saharan Africa
  26. Risk of cancer among individuals with a history of bacterial sexually transmitted infections: A population‐based study in Alberta, Canada
  27. E6/E7 Similarity to Human Papillomavirus Prototypes and Performance of HPV Testing by Cobas 4800 HPV Test and Anyplex II HPV HR
  28. Epidemiological approaches to evaluate clinical unmasking of HPV‐associated cervical lesions in the HPV vaccination era
  29. IgG and IgM Seroreactivity Against Natural HPV16 Infection and HLA‐DRB1 and ‐DQB1 Polymorphism
  30. The health-related impact of disruptions in cancer care and the Waiting Time Paradox
  31. Data from Genital, Oral, and Anal Type-specific Human Papillomavirus Concordance within Individuals and between Partners
  32. Table S1 from Genital, Oral, and Anal Type-specific Human Papillomavirus Concordance within Individuals and between Partners
  33. Table S2 from Genital, Oral, and Anal Type-specific Human Papillomavirus Concordance within Individuals and between Partners
  34. Table S3 from Genital, Oral, and Anal Type-specific Human Papillomavirus Concordance within Individuals and between Partners
  35. Table S4 from Genital, Oral, and Anal Type-specific Human Papillomavirus Concordance within Individuals and between Partners
  36. Table S5 from Genital, Oral, and Anal Type-specific Human Papillomavirus Concordance within Individuals and between Partners
  37. Table S6 from Genital, Oral, and Anal Type-specific Human Papillomavirus Concordance within Individuals and between Partners
  38. Evolution and future of cervical cancer screening: from cytology to primary HPV testing and the impact of vaccination
  39. Human papillomavirus incidence and transmission by vaccination status among heterosexual couples
  40. Genital, Oral, and Anal Type-specific Human Papillomavirus Concordance within Individuals and between Partners
  41. Inequalities in relative cancer survival by race, immigration status, income, and education for 22 cancer sites in Canada, a cohort study
  42. Naturally Acquired Genotype‐Specific HPV Seroreactivity and Subsequent HPV Detection Among Heterosexual Partners
  43. Systematic review and meta-analysis of the association between naturally induced IgG, IgM and neutralising antibodies to HPV16 and newly detected cervical HPV16 infection outcomes
  44. A Narrative Review of the Putative Etiologic Role and Diagnostic Utility of the Cervicovaginal Microbiome in Human Papillomavirus‐Associated Cervical Carcinogenesis
  45. Psychological, financial, and educational impacts of the COVID-19 pandemic among children and adolescents with cancer and their families: a systematic review and thematic analysis
  46. Will methylation assays be part of a full molecular strategy to improve clinical management of cervical neoplasia?
  47. Safety of carrageenan-based gels as preventive microbicides: a narrative review
  48. Empirical sample-specific approaches to define HPV16 and HPV18 seropositivity in unvaccinated, young, sexually active women
  49. Inequalities in relative cancer survival by race, immigration status, income, and education for 22 cancer sites in Canada, a cohort study
  50. Species‐level characterization of the cervicovaginal microbiota and its role in human papillomavirus‐associated cervical carcinogenesis
  51. Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination
  52. Impact of a carrageenan gel on viral load of genital human papillomavirus infections in sexually active women: Findings from the Carrageenan‐gel Against Transmission of Cervical Human papillomavirus (CATCH) trial
  53. Naturally developed HPV16 antibodies and risk of newly detected cervical HPV infection outcomes
  54. Use of a carrageenan‐based gel had no impact on anal HPVs 16 and 18 viral loads in gay, bisexual, and other men who have sex with men
  55. Immunosuppression and cancer risk in kidney transplant recipients: A retrospective cohort study
  56. A new initiative for the Journal of the National Cancer Institute: supporting early career investigators
  57. Scientific approaches toward improving cervical cancer elimination strategies
  58. Reaffirming our values: the Journal of the National Cancer Institute’s commitment to excellence and society
  59. Betapapillomavirus natural history and co‐detection with alphapapillomavirus in cervical samples of adult women
  60. Detection and Clearance of Type-Specific and Phylogenetically Related Genital Human Papillomavirus Infections in Young Women in New Heterosexual Relationships
  61. Acting on past lessons and learning new ones
  62. Betapapillomavirus natural history and co-detection with alphapapillomavirus in cervical samples of adult women
  63. Validation of novel DNA methylation markers in cervical precancer and cancer
  64. Prevention and control of HPV and HPV-related cancers in France: the evolving landscape and the way forward – a meeting report
  65. Association between male circumcision and human papillomavirus infection in males and females: a systematic review, meta-analysis, and meta-regression
  66. Differences in site‐specific cancer incidence by individual‐ and area‐level income in Canada from 2006 to 2015
  67. Data from Site-Specific Cancer Incidence by Race and Immigration Status in Canada 2006–2015: A Population-Based Data Linkage Study
  68. Data from Site-Specific Cancer Incidence by Race and Immigration Status in Canada 2006–2015: A Population-Based Data Linkage Study
  69. Supplementary Figure 1 from Site-Specific Cancer Incidence by Race and Immigration Status in Canada 2006–2015: A Population-Based Data Linkage Study
  70. Supplementary Figure 1 from Site-Specific Cancer Incidence by Race and Immigration Status in Canada 2006–2015: A Population-Based Data Linkage Study
  71. Supplementary Table 1 from Site-Specific Cancer Incidence by Race and Immigration Status in Canada 2006–2015: A Population-Based Data Linkage Study
  72. Supplementary Table 1 from Site-Specific Cancer Incidence by Race and Immigration Status in Canada 2006–2015: A Population-Based Data Linkage Study
  73. Supplementary Table 2 from Site-Specific Cancer Incidence by Race and Immigration Status in Canada 2006–2015: A Population-Based Data Linkage Study
  74. Supplementary Table 2 from Site-Specific Cancer Incidence by Race and Immigration Status in Canada 2006–2015: A Population-Based Data Linkage Study
  75. Supplementary Table 3 from Site-Specific Cancer Incidence by Race and Immigration Status in Canada 2006–2015: A Population-Based Data Linkage Study
  76. Supplementary Table 3 from Site-Specific Cancer Incidence by Race and Immigration Status in Canada 2006–2015: A Population-Based Data Linkage Study
  77. Supplementary Table 4 from Site-Specific Cancer Incidence by Race and Immigration Status in Canada 2006–2015: A Population-Based Data Linkage Study
  78. Supplementary Table 4 from Site-Specific Cancer Incidence by Race and Immigration Status in Canada 2006–2015: A Population-Based Data Linkage Study
  79. Pan-Canadian survey on the impact of the COVID-19 pandemic on cervical cancer screening and management: cross-sectional survey of healthcare professionals
  80. The time has come to implement primary human papillomavirus screening for cervical cancer in the United States
  81. Epidemiology of genital human papillomavirus infections in sequential male sex partners of young females
  82. Homage to Georgios Papanikolaou: A pilgrimage to his birthplace
  83. Efficacy and safety of a self-applied carrageenan-based gel to prevent human papillomavirus infection in sexually active young women (CATCH study): an exploratory phase IIB randomised, placebo-controlled trial
  84. Self-applied carrageenan-based gel to prevent human papillomavirus infection in sexually active young women: Final analysis of efficacy and safety of a randomised controlled trial
  85. Detection and clearance of type-specific and phylogenetically related genital human papillomavirus infections in young women in new heterosexual relationships
  86. Human Papillomavirus Intermittence and Risk Factors Associated With First Detections and Redetections in the Ludwig-McGill Cohort Study of Adult Women
  87. Site-Specific Cancer Incidence by Race and Immigration Status in Canada 2006–2015: A Population-Based Data Linkage Study
  88. A synthesis of evidence for cancer-specific screening interventions: A Preventive Medicine Golden Jubilee Review
  89. It takes a village: Preventive Medicine and Preventive Medicine Reports in the last decade
  90. The impact of lag time to cancer diagnosis and treatment on clinical outcomes prior to the COVID-19 pandemic: A scoping review of systematic reviews and meta-analyses
  91. Differences in site-specific cancer incidence by individual- and area-level income in Canada from 2006-2015
  92. A review of data systems for assessing the impact of HPV vaccination in selected high-income countries
  93. It takes a village: Preventive Medicine and Preventive Medicine Reports in the last decade
  94. Revisiting a neglected public health priority: Research on gun violence prevention
  95. Site-specific cancer incidence by race and immigration status in Canada 2006-2015: a population-based data linkage study
  96. Serologic Response to Human Papillomavirus Genotypes Among Unvaccinated Women: Findings From the HITCH Cohort Study
  97. A Golden Jubilee Editorial - Preventive Medicine's contributions to the science of cervical cancer elimination
  98. Preventive Medicine: Topical diversity and rigour 50 years on
  99. Prevalence of cervical human papillomavirus in Mexico, 2010–2017: analysis of 2.7 million women
  100. Human papillomavirus intermittence, redetections, and associated risk of cytological abnormalities in the Ludwig-McGill cohort study of adult women
  101. Genotyping and Cytology Triage of High-Risk HPV DNA Positive Women for Detection of Cervical High-Grade Lesions
  102. Association Between Human Leukocyte Antigen Polymorphism and Human Papillomavirus Infection in Brazilian Women
  103. Pan-Canadian survey on the impact of the COVID-19 pandemic on cervical cancer screening and management
  104. Overview of Preventive Medicine's thematic article collections– A golden jubilee editorial
  105. Association between male circumcision and human papillomavirus infection in males and females: a systematic review, meta-analysis, and meta-regression
  106. The impact of lag time to cancer diagnosis and treatment on clinical outcomes prior to the COVID-19 pandemic: a scoping review of systematic reviews and meta-analyses
  107. Ecologic Analysis of Correlates of Cervical Cancer Morbidity and Mortality in Sub-Saharan Africa
  108. Willingness to Self-Collect a Sample for HPV-Based Cervical Cancer Screening in a Well-Screened Cohort: HPV FOCAL Survey Results
  109. Human papillomavirus‐based screening at extended intervals missed fewer cervical precancers than cytology in the HPV For Cervical Cancer (HPV FOCAL) trial
  110. Male Circumcision and Genital Human Papillomavirus (HPV) Infection in Males and Their Female Sexual Partners: Findings From the HPV Infection and Transmission Among Couples Through Heterosexual Activity (HITCH) Cohort Study
  111. Cost-effectiveness of human papillomavirus vaccination in girls living in Latin American countries: A systematic review and meta-analysis
  112. Role of Human Leukocyte Antigen Allele Sharing in Human Papillomavirus Infection Transmission Among Heterosexual Couples: Findings From the HITCH Cohort Study
  113. A Review of Ethical and Legal Aspects of Gender-Neutral Human Papillomavirus Vaccination
  114. Protection to Self and to One's Sexual Partner After Human Papillomavirus Vaccination: Preliminary Analysis From the Transmission Reduction And Prevention with HPV Vaccination Study
  115. The IARC Perspective on Cervical Cancer Screening
  116. Clinical Performance of the BD Onclarity Extended Genotyping Assay for the Management of Women Positive for Human Papillomavirus in Cervical Cancer Screening
  117. Efficacy of a Carrageenan Gel in Increasing Clearance of Anal Human Papillomavirus Infections in Men: Interim Analysis of a Double-Blind, Randomized Controlled Trial
  118. Human papillomavirus genotype concordance between Anyplex II HPV28 and linear array HPV genotyping test in anogenital samples
  119. Comparative performance of the human papillomavirus test and cytology for primary screening for high‐grade cervical intraepithelial neoplasia at the population level
  120. Predicted long‐term impact of COVID ‐19 pandemic‐related care delays on cancer mortality in Canada
  121. Is Hodgkin Lymphoma Associated with Hepatitis B and C Viruses? A Systematic Review and Meta-analysis
  122. Proportion of Incident Genital Human Papillomavirus Detections not Attributable to Transmission and Potentially Attributable to Latent Infections: Implications for Cervical Cancer Screening
  123. The IARC Perspective on Cervical Cancer Screening
  124. Design and methods for the Carrageenan-gel Against Transmission of Cervical Human papillomavirus (CATCH) study: A randomized controlled trial
  125. Long-term cervical precancer outcomes after a negative DNA- or RNA-based human papillomavirus test result
  126. The noblest among noble public health goals: Preventing suicide
  127. Vaginal Microbiome Components as Correlates of Cervical Human Papillomavirus Infection
  128. Women’s acceptability of and experience with primary human papillomavirus testing for cervix screening: HPV FOCAL trial cross-sectional online survey results
  129. Lessons from an unparalleled disruption to cancer prevention and control
  130. Reply
  131. Correction to: Timeliness of diagnosis and treatment: the challenge of childhood cancers
  132. Timeliness of diagnosis and treatment: the challenge of childhood cancers
  133. Predicted long-term impact of COVID-19 pandemic-related care delays on cancer incidence and mortality in Canada
  134. Human papillomavirus vaccination in adults: impact, opportunities and challenges – a meeting report
  135. Global estimates of expected and preventable cervical cancers among girls born between 2005 and 2014: a birth cohort analysis
  136. Modeling Cervical Cancer Screening Strategies With Varying Levels of Human Papillomavirus Vaccination
  137. Efficacy of a carrageenan gel in preventing anal human papillomavirus (HPV) infection: interim analysis of the Lubricant Investigation in Men to Inhibit Transmission of HPV Infection (LIMIT-HPV) randomised controlled trial
  138. Development and evaluation of a new non-competitive Luminex immunoassay detecting antibodies against human papillomavirus types 6, 11, 16 and 18
  139. Proportion of new genital human papillomavirus detections attributable to latent infections: Implications for cervical cancer screening
  140. Cost‐effectiveness analysis of primary human papillomavirus testing in cervical cancer screening: Results from the HPV FOCAL Trial
  141. Assessment of the possible inhibitory effect of carrageenan in human papillomavirus DNA testing by polymerase chain reaction amplification
  142. A bold but morally necessary and attainable goal
  143. A Review of Canadian Cancer-Related Clinical Practice Guidelines and Resources during the COVID-19 Pandemic
  144. Evolution of Public Health Human Papillomavirus Immunization Programs in Canada
  145. Reply to: Comments on cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and meta‐analysis
  146. Sex- and Type-specific Genital Human Papillomavirus Transmission Rates Between Heterosexual Partners: A Bayesian Reanalysis of the HITCH Cohort
  147. Carrageenan as a Preventive Agent Against Human Papillomavirus Infection: A Narrative Review
  148. Assessing 10-Year Safety of a Single Negative HPV Test for Cervical Cancer Screening: Evidence from FOCAL-DECADE Cohort
  149. Association of Serum 25-Hydroxyvitamin D With Prevalence, Incidence, and Clearance of Vaginal HPV Infection in Young Women
  150. A comparison of approaches for estimating combined population attributable risks (PARs) for multiple risk factors
  151. A Pooled Analysis to Compare the Clinical Characteristics of Human Papillomavirus–positive and -Negative Cervical Precancers
  152. Dual staining for p16/Ki‐67 to detect high‐grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study
  153. Transmission reduction and prevention with HPV vaccination (TRAP-HPV) study protocol: a randomised controlled trial of the efficacy of HPV vaccination in preventing transmission of HPV infection in heterosexual couples
  154. Defining benchmarks for tolerable risk thresholds in cancer screening: Impact of HPV vaccination on the future of cervical cancer screening
  155. Invited Commentary: Rethinking Cervical Cancer Elimination in Terms of Lifetime Risk Rather Than Arbitrarily Defined Age-Standardized Incidence Rates
  156. Correlation between cervical HPV DNA detection and HPV16 seroreactivity measured with L1-only and L1+L2 viral capsid antigens
  157. Modeling the Balance of Benefits and Harms of Cervical Cancer Screening with Cytology and Human Papillomavirus Testing
  158. Characterization of the Vaginal Microbiome in Women of Reproductive Age From 5 Regions in Brazil
  159. Directionality of Genital Human Papillomavirus Infection Transmission Within Heterosexual Couples: A Systematic Review and Meta-analysis
  160. Prevention and control of HPV infection and HPV-related cancers in Colombia- a meeting report
  161. Cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and meta‐analysis
  162. Challenges of False Positive and Negative Results in Cervical Cancer Screening
  163. Surgeon and hospital volume outcomes in bariatric surgery: a population-level study
  164. Challenges of false positive and negative results in cervical cancer screening
  165. Fruits and vegetables and cervical cancer: a systematic review and meta-analysis
  166. Lubricant Investigation in Men to Inhibit Transmission of HPV Infection (LIMIT-HPV): design and methods for a randomised controlled trial
  167. Genome‐wide DNA methylation profiling identifies two novel genes in cervical neoplasia
  168. The potential harms of personal lubricants
  169. Corrigendum to “Cancers attributable to infections in Canada” [Prev. Med. 122 (2019) 109–117]
  170. Corrigendum to “Estimates of the future burden of cancer attributable to infections in Canada” [Prev. Med. 122 (2019) 118–127]
  171. The role of healthcare providers in HPV vaccination programs – A meeting report
  172. Comparison of HPV-16 and HPV-18 Genotyping and Cytological Testing as Triage Testing Within Human Papillomavirus–Based Screening in Mexico
  173. Viral load of human papillomavirus types 16/18/31/33/45 as a predictor of cervical intraepithelial neoplasia and cancer by age
  174. Latency of tobacco smoking for head and neck cancer among HPV‐positive and HPV‐negative individuals
  175. Methylation estimates the risk of precancer in HPV-infected women with discrepant results between cytology and HPV16/18 genotyping
  176. Decline in vaccine-type human papillomavirus prevalence in young men from a Midwest metropolitan area of the United States over the six years after vaccine introduction
  177. Vaccination of Young Women Decreases Human Papillomavirus Transmission in Heterosexual Couples: Findings from the HITCH Cohort Study
  178. Determinants of Acquisition and Clearance of Human Papillomavirus Infection in Previously Unexposed Young Women
  179. Inter- and Intraprovincial Inequities in Public Coverage of Cancer Drug Programs across Canada: A Plea for the Establishment of a Pan-Canadian Pharmacare Program
  180. Disease detection at the 48‐month exit round of the HPV FOCAL cervical cancer screening trial in women per‐protocol eligible for routine screening
  181. Human Papillomavirus Viral Load and Transmission in Young, Recently Formed Heterosexual Couples
  182. Cancers attributable to infections in Canada
  183. Estimates of the future burden of cancer attributable to infections in Canada
  184. The burden of cancer attributable to modifiable risk factors in Canada: Methods overview
  185. Predictive Value of HPV Testing in Self-collected and Clinician-Collected Samples Compared with Cytology in Detecting High-grade Cervical Lesions
  186. Genetic variants in CYP and GST genes, smoking and risk for head and neck cancers: a gene–environment interaction hospital-based case–control study among Canadian Caucasians
  187. Improving the reporting of cancer-specific mortality and survival in research using cancer registry data
  188. Predictors of dysplastic and neoplastic progression of Barrett’s esophagus
  189. The future burden of cancer in Canada: Long-term cancer incidence projections 2013–2042
  190. Lack of association between human papillomavirus types 6 and 11 genetic variants and cervical abnormalities: The Ludwig-McGill cohort study
  191. Hand-to-genital and genital-to-genital transmission of human papillomaviruses between male and female sexual partners (HITCH): a prospective cohort study
  192. Efficacy of a Carrageenan gel Against Transmission of Cervical HPV (CATCH): interim analysis of a randomized, double-blind, placebo-controlled, phase 2B trial
  193. Human Papillomavirus Vaccine Effectiveness and Herd Protection in Young Women
  194. Limitations of simulation models for cervical cancer screening – Authors' reply
  195. Human Papillomavirus Infection and Transmission Among Couples Through Heterosexual Activity (HITCH) Cohort Study: Protocol Describing Design, Methods, and Research Goals
  196. Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction
  197. Increased risk of oropharyngeal cancers mediated by oral human papillomavirus infection: Results from a Canadian study
  198. Prevention of cervical cancer in Latin America: Future challenges and opportunities
  199. Use of HPV testing in cervical cancer screening services in Mexico, 2008-2018: a nationwide database study
  200. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated women: a modelling study
  201. Assessing the Time Dependence of Prognostic Values of Cytology and Human Papillomavirus Testing in Cervical Cancer Screening
  202. Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial
  203. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months
  204. Restoring Dignity in Academic Publishing Is a Collective Duty
  205. HLA and KIR Associations of Cervical Neoplasia
  206. Validation of a New HPV Self-Sampling Device for Cervical Cancer Screening
  207. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months
  208. Epidemiology of Any and Vaccine-Type Anogenital Human Papillomavirus Among 13–26-Year-Old Young Men After HPV Vaccine Introduction
  209. Estimating the current and future cancer burden in Canada: methodological framework of the Canadian population attributable risk of cancer (ComPARe) study
  210. Human Papillomavirus Infection and Transmission Among Couples Through Heterosexual Activity (HITCH) Cohort Study: Protocol Describing Design, Methods, and Research Goals (Preprint)
  211. Human papillomavirus vaccination and the role of herd effects in future cancer control planning: a review
  212. Journal editors as curators of scholarship: A case study in repairing the scientific record
  213. Who's Not Protected in the Herd? Factors Associated with Vaccine-Type HPV in Unvaccinated Women
  214. Validation of a new HPV self-sampling device for cervical cancer screening: The Cervical and Self-Sample In Screening (CASSIS) study
  215. Correction: Defining the genetic susceptibility to cervical neoplasia—A genome-wide association study
  216. Self-sampling for cervical cancer screening: Empowering women to lead a paradigm change in cancer control
  217. Persistence of human papillomavirus 16, 18 and 52 variants in Inuit women from Northern Quebec, Canada
  218. The performance of mobile screening units in a breast cancer screening program in Brazil
  219. Human Papillomavirus Vaccination: Making Sense of the Public Controversy
  220. Mobile Screening Units for the Early Detection of Cancer: A Systematic Review
  221. Non-Vaccine-Type HPV Prevalence after Vaccine Introduction
  222. Aetiological heterogeneity of head and neck squamous cell carcinomas: the role of human papillomavirus infections, smoking and alcohol
  223. Estimating HPV DNA Deposition Between Sexual Partners Using HPV Concordance, Y Chromosome DNA Detection, and Self-reported Sexual Behaviors
  224. Argon plasma coagulation treatment of anal high-grade squamous intraepithelial lesions in men who have sex with men living with HIV: results of a 2-year prospective pilot study
  225. Defining the genetic susceptibility to cervical neoplasia—A genome-wide association study
  226. Y Chromosome DNA in Womenʼs Vaginal Samples as a Biomarker of Recent Vaginal Sex and Condom Use With Male Partners in the HPV Infection and Transmission Among Couples Through Heterosexual Activity Cohort Study
  227. Optimizing secondary prevention of cervical cancer: Recent advances and future challenges
  228. Population health intervention research: A renewed commitment to promoting a science of solutions
  229. The Downside of the Shifting Paradigm of Scholarly Publishing in the Biomedical Sciences: Predatory Publishing
  230. L’inconvénient du changement de paradigme dans l’édition savante en sciences biomédicales : l’arrivée des éditeurs prédateurs
  231. Assortativity and Mixing by Sexual Behaviors and Sociodemographic Characteristics in Young Adult Heterosexual Dating Partnerships
  232. Human papillomavirus genotypes and risk of head and neck cancers: Results from the HeNCe Life case-control study
  233. Approaches for triaging women who test positive for human papillomavirus in cervical cancer screening
  234. Independent Scientists Provide Guidance for the Future of Cervical Cancer Screening
  235. Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm
  236. Cervical Infection with Cutaneous Beta and Mucosal Alpha Papillomaviruses
  237. Ottawa Statement from the Sparking Solutions Summit on Population Health Intervention Research
  238. Aptima HPV Assay versus Hybrid Capture® 2 HPV test for primary cervical cancer screening in the HPV FOCAL trial
  239. Determinants of Cervical Cancer Screening Accuracy for Visual Inspection with Acetic Acid (VIA) and Lugol’s Iodine (VILI) Performed by Nurse and Physician
  240. Comparison of Triage Strategies for HPV-Positive Women: Canadian Cervical Cancer Screening Trial Results
  241. Does hormonal therapy for fertility preservation affect the survival of young women with early-stage endometrial cancer?
  242. Epidemiologic Evaluation of Human Papillomavirus Type Competition and the Potential for Type Replacement Post-Vaccination
  243. Disease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial
  244. Distribution of Vaccine-Type Human Papillomavirus Does Not Differ by Race or Ethnicity Among Unvaccinated Young Women
  245. HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer
  246. Substantial Decline in Vaccine-Type Human Papillomavirus (HPV) Among Vaccinated Young Women During the First 8 Years After HPV Vaccine Introduction in a Community
  247. Nonlinear association between betel quid chewing and oral cancer: Implications for prevention
  248. Population-based prevalence of cervical infection with human papillomavirus genotypes 16 and 18 and other high risk types in Tlaxcala, Mexico
  249. Human papillomavirus testing versus cytology in primary cervical cancer screening: End-of-study and extended follow-up results from the Canadian cervical cancer screening trial
  250. Should we lower the age for routine HPV vaccination in the United States?
  251. Recommendations for Implementing Human Papillomavirus-Based Cervical Cancer Screening: Lessons Learned from the HPV FOCAL Trial
  252. Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naïve women: results from the control arm of a phase II HPV-16/18 vaccine trial
  253. A collaboration between cousins: The Canadian Journal of Public Health and the Canadian Society for Epidemiology and Biostatistics
  254. Periodontal diseases and risk of oral cancer in Southern India: Results from the HeNCe Life study
  255. Cervical Infection With Vaccine-Associated Human Papillomavirus (HPV) Genotypes as a Predictor of Acquisition and Clearance of Other HPV Infections
  256. Reproductive and genital health and risk of cervical human papillomavirus infection: results from the Ludwig-McGill cohort study
  257. Correlates of women’s intentions to be screened for human papillomavirus for cervical cancer screening with an extended interval
  258. Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none
  259. Triage strategies in cervical cancer detection in Mexico: methods of the FRIDA Study
  260. Assessment of mediators of racial disparities in cervical cancer survival in the United States
  261. World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2-3 and screen-and-treat strategies to prevent cervical cancer
  262. Human papillomavirus variants among Inuit women in northern Quebec, Canada
  263. Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial
  264. Assortative mixing as a source of bias in epidemiological studies of sexually transmitted infections: the case of smoking and human papillomavirus
  265. Risk of Human Papillomavirus (HPV) Infection and Cervical Neoplasia after Pregnancy
  266. What makes an eLife paper in epidemiology and global health?
  267. An elusive low-hanging fruit for public health: Gun violence prevention
  268. No role for human papillomavirus infection in oral cancers in a region in southern India
  269. HPV DNA testing with cytology triage in cervical cancer screening: Influence of revealing HPV infection status
  270. Sobering realizations in cancer prevention and screening and their lessons
  271. Incidence, Persistence, and Determinants of Human Papillomavirus Infection in a Population of Inuit Women in Northern Quebec
  272. Projected Impact of HPV and LBC Primary Testing on Rates of Referral for Colposcopy in a Canadian Cervical Cancer Screening Program
  273. Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: Data from the ATHENA trial
  274. Perfect is the Enemy of Good: Going to the War on Cancer with Less Evidence than We Could Have
  275. Urologist referral delay and its impact on survival after radical cystectomy for bladder cancer
  276. Determinants of baseline seroreactivity to human papillomavirus type 16 in the Ludwig-McGill cohort study
  277. Sexual Transmission of Oral Human Papillomavirus Infection among Men
  278. Women’s intentions to self-collect samples for human papillomavirus testing in an organized cervical cancer screening program
  279. Evaluation of Human Papillomavirus Type Replacement Postvaccination Must Account for Diagnostic Artifacts: Masking of HPV52 by HPV16 in Anogenital Specimens
  280. Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: A transmission-dynamic modelling study
  281. Epidemiology of cervical cancer
  282. Screening for cervical cancer
  283. Striving for excellence while adapting to change: Redefining our mission of serving the preventive medicine community
  284. Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs
  285. Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16
  286. Screening histories and contact with physicians as determinants of cervical cancer risk in Montreal, Quebec
  287. Predictors of preoperative delays before radical cystectomy for bladder cancer in Q uebec, C anada: a population‐based study
  288. HPV testing with cytology triage for cervical cancer screening in routine practice
  289. Global Genomic Diversity of Human Papillomavirus 6 Based on 724 Isolates and 190 Complete Genome Sequences
  290. Determinants of Prevalent Human Papillomavirus in Recently Formed Heterosexual Partnerships: A Dyadic-Level Analysis
  291. Determinants of Human Papillomavirus Coinfections among Montreal University Students: The Influence of Behavioral and Biologic Factors
  292. Making Prospective Registration of Observational Research a Reality
  293. Embracing a new era in cervical cancer screening
  294. The road ahead for cervical cancer prevention and control
  295. Is there a need for a new journal devoted to preventive medicine?
  296. cobas®4800 HPV Test, a real-time polymerase chain reaction assay for the detection of human papillomavirus in cervical specimens
  297. Comprehensive Control of Human Papillomavirus Infections and Related Diseases
  298. Comprehensive Control of Human Papillomavirus Infections and Related Diseases
  299. Comprehensive Control of Human Papillomavirus Infections and Related Diseases
  300. The association between human leukocyte antigen (HLA)-G polymorphisms and human papillomavirus (HPV) infection in Inuit women of northern Quebec
  301. Human papillomavirus type 56 polymorphism in Canadian women with and without cervical lesions
  302. Comprehensive Control of Human Papillomavirus Infections and Related Diseases
  303. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine
  304. Lung Cancer Screening: Review and Performance Comparison Under Different Risk Scenarios
  305. Polymorphisms in Genes Involved in Folate Metabolism Modify the Association of Dietary and Circulating Folate and Vitamin B-6 with Cervical Neoplasia
  306. Combatting obesity — A helping hand from the business community
  307. Counterpoint: Cervical Cancer Screening Guidelines--Approaching the Golden Age
  308. The frequency of HLA alleles in a population of Inuit women of northern Quebec
  309. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: A transmission-dynamic modeling study
  310. Women's intentions to receive cervical cancer screening with primary human papillomavirus testing
  311. Vaccinating Girls and Boys with Different Human Papillomavirus Vaccines: Can It Optimise Population-Level Effectiveness?
  312. Polymorphism in the promoter region of the Toll-like receptor 9 gene and cervical human papillomavirus infection
  313. Human papillomavirus type 16 viral load measurement as a predictor of infection clearance
  314. Epidemiologic Approaches to Evaluating the Potential for Human Papillomavirus Type Replacement Postvaccination
  315. Factors associated with cervical cancer screening uptake among Inuit women in Nunavik, Quebec, Canada
  316. Influence of Postoperative Infectious Complications on Long-Term Survival of Lung Cancer Patients: A Population-Based Cohort Study
  317. 77 PREOPERATIVE DELAYS PRIOR TO RADICAL CYSTECTOMY IN PATIENTS WITH BLADDER CANCER: A POPULATION-BASED STUDY
  318. Response
  319. Assessment of the performance of algorithms for cervical cancer screening: Evidence from the Ludwig–McGill cohort study
  320. Accuracy of p53 Codon 72 Polymorphism Status Determined by Multiple Laboratory Methods: A Latent Class Model Analysis
  321. Carrageenan Against Transmission of Cervical Human papillomavirus (HPV)
  322. Vaccination and Screening in Cervical Cancer Control and Prevention
  323. Preventive Medicine: New Editorial Office but the Same Vision
  324. The Canadian Cervical Cancer Screening Trial of human papillomavirus (HPV) testing versus Pap cytology
  325. Towards more eclectic evidence-based medicine in cancer prevention and control
  326. Human papillomavirus type 52 polymorphism and high-grade lesions of the uterine cervix
  327. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial – the HPV FOCAL Study
  328. Human Papillomavirus and Cancer Prevention: Gaps in Knowledge and Prospects for Research, Policy, and Advocacy
  329. Cervical human papillomavirus detection is not affected by menstrual phase
  330. Population-Level Impact of the Bivalent, Quadrivalent, and Nonavalent Human Papillomavirus Vaccines: A Model-Based Analysis
  331. Patterns of persistent genital human papillomavirus infection among women worldwide: A literature review and meta-analysis
  332. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis
  333. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer
  334. Performance of an Adipokine Pathway-Based Multilocus Genetic Risk Score for Prostate Cancer Risk Prediction
  335. Outcomes and Cost Comparisons After Introducing a Robotics Program for Endometrial Cancer Surgery
  336. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer
  337. Inuit women's attitudes and experiences towards cervical cancer and prevention strategies in Nunavik, Quebec
  338. Circulating Biomarkers of Iron Storage and Clearance of Incident Human Papillomavirus Infection
  339. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer
  340. Burden of disease, health indicators and challenges for epidemiology in North America
  341. Dry self-sampling versus provider-sampling of cervicovaginal specimens for human papillomavirus detection in the Inuit population of Nunavik, Quebec
  342. Human Papillomavirus (HPV) DNA Triage of Women with Atypical Squamous Cells of Undetermined Significance with cobas 4800 HPV and Hybrid Capture 2 Tests for Detection of High-Grade Lesions of the Uterine Cervix
  343. Comparison of human papillomavirus testing and cytology for cervical cancer screening in a primary health care setting in the Democratic Republic of the Congo
  344. Human leukocyte antigen G polymorphism is associated with an increased risk of invasive cancer of the uterine cervix
  345. Epidemiology, natural history and risk factors for anal intraepithelial neoplasia
  346. Ano-genital human papillomavirus type 97 infection is detected in Canadian men but not women at risk or infected with the human immunodeficiency virus
  347. Biomarkers of oxidant load and type-specific clearance of prevalent oncogenic human papillomavirus infection: Markers of immune response?
  348. Genital Transmission of Human Papillomavirus in Recently Formed Heterosexual Couples
  349. Epidemiology and burden of HPV infection and related diseases: Implications for prevention strategies
  350. The Impact of Anogenital Warts on Health-Related Quality of Life: A 6-Month Prospective Study
  351. Human Papillomavirus Vaccines
  352. Human papillomavirus vaccines
  353. Generic Microtiter Plate Assay for Triaging Clinical Specimens Prior to Genotyping of Human Papillomavirus DNA via Consensus PCR
  354. Incremental Impact of Adding Boys to Current Human Papillomavirus Vaccination Programs: Role of Herd Immunity
  355. The psychosocial impact of an abnormal cervical smear result
  356. Optimizing technology for cervical cancer screening in high-resource settings
  357. Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada
  358. Human leukocyte antigen (HLA)-E and HLA-G polymorphisms in human papillomavirus infection susceptibility and persistence
  359. HAART and Progression to High-Grade Anal Intraepithelial Neoplasia in Men Who Have Sex with Men and Are Infected with HIV
  360. Loss of quality of life associated with genital warts: baseline analyses from a prospective study
  361. Use of Non-Steroidal Anti-Inflammatory Drugs and Prostate Cancer Risk: A Population-Based Nested Case-Control Study
  362. Prevalence and Determinants of High-Risk Human Papillomavirus Infection in Women From a Sub-Saharan African Community
  363. Associations of dietary dark-green and deep-yellow vegetables and fruits with cervical intraepithelial neoplasia: modification by smoking
  364. Human Papillomavirus (HPV) DNA Triage of Women with Atypical Squamous Cells of Undetermined Significance with Amplicor HPV and Hybrid Capture 2 Assays for Detection of High-Grade Lesions of the Uterine Cervix
  365. Economic evaluation of strategies for managing women with equivocal cytological results in Brazil
  366. Human papillomavirus (HPV) types 16, 18, 31, 45 DNA loads and HPV-16 integration in persistent and transient infections in young women
  367. Integrating novel primary- and secondary-prevention strategies: the next challenge for cervical cancer control
  368. Human Papillomavirus Infection and Reinfection in Adult Women: the Role of Sexual Activity and Natural Immunity
  369. Persistent HPV Infection and Cervical Cancer Risk: Is the Scientific Rationale for Changing the Screening Paradigm Enough?
  370. Radiodiagnostic Imaging in Pregnancy and the Risk of Childhood Malignancy: Raising the Bar
  371. Dietary consumption of antioxidant nutrients and risk of incident cervical intraepithelial neoplasia
  372. Are endometrial polyps true cancer precursors?
  373. Episomal and integrated human papillomavirus type 16 loads and anal intraepithelial neoplasia in HIV-seropositive men
  374. No Association between Endogenous Retinoic Acid and Human Papillomavirus Clearance or Incident Cervical Lesions in Brazilian Women
  375. Polymorphism of the capsid L1 gene of human papillomavirus types 31, 33, and 35
  376. The impact of intolerance of uncertainty on anxiety after receiving an informational intervention about HPV: A randomised controlled study
  377. Awareness and Knowledge about Human Papillomavirus Among Inuit Women in Nunavik, Quebec
  378. What is the role of HPV typing in the United States now and in the next five years in a vaccinated population?
  379. Determinants of Human Papillomavirus Infection Among Inuit Women of Northern Quebec, Canada
  380. A randomized controlled trial of Human Papillomavirus (HPV) testing for cervicalcancer screening: trial design and preliminary results (HPV FOCAL Trial)
  381. Diet and serum micronutrients in relation to cervical neoplasia and cancer among low-income Brazilian women
  382. Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: A meta-analysis
  383. Use of the Normalized Absorbance Ratio as an Internal Standardization Approach To Minimize Measurement Error in Enzyme-Linked Immunosorbent Assays for Diagnosis of Human Papillomavirus Infection
  384. Human Papillomavirus Infections Among Couples in New Sexual Relationships
  385. Influence of Partnerʼs Infection Status on Prevalent Human Papillomavirus Among Persons With a New Sex Partner
  386. Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era
  387. Validation of dot blot hybridization and denaturing high performance liquid chromatography as reliable methods for TP53 codon 72 genotyping in molecular epidemiologic studies
  388. Invited Commentary: Human Papillomavirus Infection and Risk of Cervical Precancer--Using the Right Methods to Answer the Right Questions
  389. Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis
  390. A New Generation of Studies of Human Papillomavirus DNA Testing in Cervical Cancer Screening
  391. Effectiveness of Cervical Cancer Screening at Different Ages
  392. Determinants of delays in treatment initiation in children and adolescents diagnosed with leukemia or lymphoma in Canada
  393. Brief Research Report: Uncertainty-Inducing and Reassuring Facts About HPV: A Descriptive Study of French Canadian Women
  394. Epidemiologyʼs Contributions to a Nobel Prize Recognition
  395. The Expected Impact of HPV Vaccination on the Accuracy of Cervical Cancer Screening: The Need for a Paradigm Change
  396. Managing low grade and borderline cervical abnormalities
  397. Is the UK ready to embrace HPV testing?
  398. Low-risk human papillomavirus type 6 DNA load and integration in cervical samples from women with squamous intraepithelial lesions
  399. Prevalence, Clearance, and Incidence of Anal Human Papillomavirus Infection in HIV‐Infected Men: The HIPVIRG Cohort Study
  400. Persistence of an Incident Human Papillomavirus Infection and Timing of Cervical Lesions in Previously Unexposed Young Women
  401. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older
  402. Prognostic Value of Measuring Load of Human Papillomavirus DNA in Cervical Samples: An Elusive Target
  403. Bernard Duval: The Architect of Quebec’s HPV Immunization Programme
  404. How Multidisciplinary Research Advanced the Mission of Cervical Cancer Prevention
  405. Infectious Diseases and Cancer: HPV
  406. Integrating Human Papillomavirus Vaccination in Cervical Cancer Control Programmes
  407. Detection and Typing of Human Papillomavirus Nucleic Acids in Biological Fluids
  408. Prevalence and Age Distribution of Human Papillomavirus Infection in a Population of Inuit Women in Nunavik, Quebec
  409. Delays in diagnosis and treatment among children and adolescents with cancer in Canada
  410. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: A multi-regional health economic analysis
  411. Cost-effectiveness analysis: An essential tool to inform public health policy in cervical cancer prevention
  412. Genotyping of Human Papillomavirus DNA in Anal Biopsies and Anal Swabs Collected From HIV-Seropositive Men With Anal Dysplasia
  413. Interaction between polymorphisms of the Human Leukocyte Antigen and HPV-16 Variants on the risk of invasive cervical cancer
  414. Use of latent class models to accommodate inter-laboratory variation in assessing genetic polymorphisms associated with disease risk
  415. Integration of Human Papillomavirus Vaccination and Cervical Cancer Screening in Latin America and the Caribbean
  416. Recommendations for Cervical Cancer Prevention in Latin America and the Caribbean
  417. Influence of human papillomavirus type 16 (HPV-16) E2 polymorphism on quantification of HPV-16 episomal and integrated DNA in cervicovaginal lavages from women with cervical intraepithelial neoplasia
  418. Type‐Specific Duration of Human Papillomavirus Infection: Implications for Human Papillomavirus Screening and Vaccination
  419. Human papillomavirus vaccination and screening as the new paradigm in cervical cancer prevention
  420. Commentary: Smoking and human papillomavirus infection: the pursuit of credibility for an epidemiologic association
  421. Cervical cancer screening following prophylactic human papillomavirus vaccination
  422. Reassessing the Epidemiology of Human Papillomavirus Infection: Back to Basics
  423. Human papillomavirus infection and oral cancer: A case-control study in Montreal, Canada
  424. Ovarian cancer and oral contraceptives
  425. Selected class I and class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia
  426. Vaccination against human papillomavirus
  427. Response to Pretorius and Belinson
  428. BROGLY ET AL. RESPOND
  429. Newly-isolated HPV97, related to HPV18 and 45 is frequently detected in HIV-positive men from the montreal area
  430. Human Papillomavirus DNA versus Papanicolaou Screening Tests for Cervical Cancer
  431. Haptoglobin phenotype and risk of cervical neoplasia: A case-control study
  432. Confirmatory Real-Time PCR Assay for Human Papillomavirus (HPV) Type 52 Infection in Anogenital Specimens Screened for HPV Infection with the Linear Array HPV Genotyping Test
  433. THE AUTHORS REPLY
  434. Cost-effectiveness of HPV 16, 18 vaccination in Brazil
  435. Prophylactic human papillomavirus vaccines: potential for sea change
  436. Process of care failures in invasive cervical cancer: Systematic review and meta-analysis
  437. HLA Polymorphisms and Cervical Human Papillomavirus Infection in a Cohort of Montreal University Students
  438. Multiparameter Calibration of a Natural History Model of Cervical Cancer
  439. Cervical cancer screening following the implementation of prophylactic human papillomavirus vaccination
  440. Reproductive Health of Adolescent Girls Perinatally Infected With HIV
  441. A New Window into the Natural History of Human Papillomavirus Infection: A View from the ALTS (Atypical Squamous Cells of Undetermined Significance/Low‐Grade Squamous Intraepithelial Lesions Triage Study) Trial
  442. Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis
  443. Re: Human Papillomavirus Type 16 and 18 Variants: Race-Related Distribution and Persistence
  444. Epidemiological methods: a view from the Americas
  445. Insulin-like Growth Factor-I and Risk of High-Grade Cervical Intraepithelial Neoplasia
  446. High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18
  447. Diagnosis delays in childhood cancer
  448. Koilocytosis in Oral Squamous Cell Carcinoma: What Does It Mean?
  449. Viral load of episomal and integrated forms of human papillomavirus type 33 in high-grade squamous intraepithelial lesions of the uterine cervix
  450. Polymorphism of the L1 Capsid Gene and Persistence of Human Papillomavirus Type 52 Infection in Women at High Risk or Infected by HIV
  451. Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK
  452. Human Papillomavirus Infections With Multiple Types and Risk of Cervical Neoplasia
  453. Cancer Precursors
  454. Lack of Agreement Between Cervicography and Cytology and the Effect of Human Papillomavirus Infection and Viral Load
  455. Human Papillomavirus Type 33 Polymorphisms and High‐Grade Squamous Intraepithelial Lesions of the Uterine Cervix
  456. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination
  457. Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts
  458. Chapter 6: Epidemiology and transmission dynamics of genital HPV infection
  459. Chapter 29: Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer
  460. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: Design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST)
  461. Is HPV testing with cytological triage a more logical approach in cervical cancer screening?
  462. Human Papillomavirus Infections with Multiple Types and Risk of Cervical Neoplasia
  463. Enhanced Detection and Typing of Human Papillomavirus (HPV) DNA in Anogenital Samples with PGMY Primers and the Linear Array HPV Genotyping Test
  464. Diversity of cutaneous human papillomavirus types in individuals with and without skin lesion
  465. Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population
  466. Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
  467. Managing low-grade cervical lesions
  468. The epidemiology of genital human papillomavirus infection
  469. Human papillomavirus testing improves the accuracy of colposcopy in detection of cervical intraepithelial neoplasia
  470. Advances in Prevention of Cervical Cancer and Other Human Papillomavirus-Related Diseases
  471. Modeling the Sexual Transmissibility of Human Papillomavirus Infection using Stochastic Computer Simulation and Empirical Data from a Cohort Study of Young Women in Montreal, Canada
  472. Epidemiology As a Tool to Reveal Inequalities in Breast Cancer Care
  473. Epidemiology of Oncogenic and Nononcogenic HPV Types, and the Evidence for Differences in Their Sexual Transmissibility
  474. Associations between serum carotenoids and tocopherols and type-specific HPV persistence: The Ludwig-McGill cohort study
  475. Visual inspection as a cervical cancer screening method in a primary health care setting in Africa
  476. High-risk human papillomavirus infection of the genital tract of women with a previous history or current high-grade vulvar intraepithelial neoplasia
  477. Comparison of Psychosocial Outcomes in Head and Neck Cancer Patients Receiving a Coping Strategies Intervention and Control Subjects Receiving No Intervention
  478. Management of low-grade cervical lesions in young women
  479. Efficacy of a Bivalent L1 Virus-Like Particle Vaccine in Prevention of Infection With Human Papillomavirus Types 16 and 18 in Young Women: A Randomized, Controlled Trial
  480. Modifiable Risk Factors Associated with Clearance of Type-Specific Cervical Human Papillomavirus Infections in a Cohort of University Students
  481. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control
  482. Different P105 Promoter Activities among Natural Variants of Human Papillomavirus Type 18
  483. Efficacy of a Bivalent L1 Virus-Like Particle Vaccine in Prevention of Infection With Human Papillomavirus Types 16 and 18 in Young Women: A Randomized Trial
  484. The Role of Human Papillomaviruses in Cancer
  485. The p53 codon 72 polymorphism and risk of high-grade cervical intraepithelial neoplasia
  486. The Laboratory Diagnosis of Genital Human Papillomavirus Infections
  487. Role and limitations of epidemiology in establishing a causal association
  488. Screening every three years, instead of annually, would result in a small increase in risk of cervical cancer
  489. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
  490. Rapport du Forum Pancanadien sur la Prévention et la Maîtrise du Cancer du col Utérin de 2003
  491. Report of the 2003 Pan-Canadian Forum on Cervical Cancer Prevention and Control
  492. Polio vaccines, Simian Virus 40, and human cancer: the epidemiologic evidence for a causal association
  493. Silver leaf nylon dressing to prevent radiation dermatitis in patients undergoing chemotherapy and external beam radiotherapy to the perineum
  494. Intensity of drug injection as a determinant of sustained injection cessation among chronic drug users: the interface with social factors and service utilization
  495. An overview of epidemiological and public health research on HPVs presented at the 21st International Papillomavirus Conference in Mexico City, 20-26 February 2004
  496. Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine
  497. Male Circumcision and AIDS in Africa
  498. Human papillomavirus and cervical dysplasia in Nunavut: prelude to a screening strategy
  499. Prognostic significance of lymph node variables and human papillomavirus DNA in invasive vulvar carcinoma
  500. Evaluation of a convenient enzyme immunoassay to assess the quality of genital specimens submitted for the detection of human papillomavirus DNA by consensus PCR
  501. Cancer of the Uterine Cervix
  502. Epidemiology of Cervical, Vulvar, and Vaginal Cancers
  503. Other Gynecologic Cancers: endometrial, ovarian, vulvar and vaginal cancers
  504. Randomized controlled trials of HPV testing and pap cytology: Toward evidence-based cervical cancer prevention
  505. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis
  506. p53 Codon 72 Polymorphism and Cervical Neoplasia: A Meta-Analysis Review
  507. Electrofulguration for Low-Grade Squamous Intraepithelial Lesions of the Cervix (CIN 1)
  508. Are we ready for a paradigm change in cervical cancer screening?
  509. Dietary Intake and Risk of Persistent Human Papillomavirus (HPV) Infection: The Ludwig‐McGill HPV Natural History Study
  510. Modeling the Time Dependence of the Association between Human Papillomavirus Infection and Cervical Cancer Precursor Lesions
  511. Innovations in understanding the biology of cervical cancer
  512. Toward a reduction of the global burden of cervical cancer
  513. The Epidemiology of Cervical Cancer
  514. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine
  515. Computer Programs for Epidemiologists–PEPI Version 4.0
  516. Occurrence of Cervical Infection with Multiple Human Papillomavirus Types is Associated with Age and Cytologic Abnormalities
  517. Epidemiologic correlates of antibody response to human papillomavirus among women at low risk of cervical cancer
  518. Other gynecologic cancers
  519. Cancer of the uterine cervix
  520. Prospects for controlling cervical cancer at the turn of the century
  521. Is Colposcopy Warranted in Women with External Anogenital Warts?
  522. Herpes simplex virus type II is not a cofactor to human papillomavirus in cancer of the uterine cervix
  523. Towards More Effective Public Health Programming for Injection Drug Users: Development and Evaluation of the Injection Drug User Quality of Life Scale
  524. Cervical cancer control, priorities and new directions
  525. Viral load as a predictor of the risk of cervical intraepithelial neoplasia
  526. Estrogen Replacement Therapy and Risk of Ovarian Cancer in Postmenopausal Women
  527. Estrogen Replacement Therapy and Risk of Ovarian Cancer in Postmenopausal WomenDifferences in Success Rates of Noninvasive VentilationSpirituality and Chronic IllnessPrematurity and Later Cognitive OutcomesAspiration of a Dental Appliance in a Patient ...
  528. Evidence-based policy recommendations on cancer screening and prevention
  529. Past, present, and future of HPV research: highlights from the 19th International Papillomavirus Conference-HPV2001
  530. Detection of human herpes virus type 6 DNA in precancerous lesions of the uterine cervix
  531. Persistent HPV infection is associated with a greater risk of developing cervical lesions than a single positive test
  532. Polymorphisms of the Human Leukocyte Antigen DRB1 and DQB1 Genes and the Natural History of Human Papillomavirus Infection
  533. Use of PGMY Primers in L1 Consensus PCR Improves Detection of Human Papillomavirus DNA in Genital Samples
  534. Predictive Factors for Diagnosis of Advanced-Stage Squamous Cell Carcinoma of the Head and Neck
  535. Cancer Precursors
  536. Persistent human papillomavirus infection and cervical neoplasia
  537. Assessing the gain in diagnostic performance when combining two diagnostic tests
  538. HIV-Positive Notification and Behavior Changes in Montreal Injection Drug Users
  539. Cervical Coinfection with Human Papillomavirus (HPV) Types as a Predictor of Acquisition and Persistence of HPV Infection
  540. Oncogenic Human Papillomavirus Infection and Cervical Lesions in Aboriginal Women of Nunavut, Canada
  541. Nonisotopic Detection of Human Papillomavirus DNA in Clinical Specimens Using a Consensus PCR and a Generic Probe Mix in an Enzyme-Linked Immunosorbent Assay Format
  542. Repeatability of sexual history in longitudinal studies on HPV infection and cervical neoplasia: determinants of reporting error at follow-up interviews
  543. Toward a reduction of the global burden of cervical cancer
  544. Cervical-cancer screening beyond the year 2000
  545. Analysis of Human Papillomavirus in Schneiderian Papillomas as Compared to Chronic Sinusitis and Normal Nasal Mucosa
  546. Comparison of Endocervical Curettage and Endocervical Brushing
  547. Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia
  548. Risk behaviour change and HIV infection among injection drug users in Montreal
  549. p53 polymorphism in codon 72 and risk of human papillomavirus‐induced cervical cancer: effect of inter‐laboratory variation
  550. The influence of parental age on the risk of Wilms' tumour
  551. Comparison of endocervical curettage and endocervical brushing
  552. Determinants of Low-Risk and High-Risk Cervical Human Papillomavirus Infections in Montreal University Students
  553. Evaluation of the potential promoting effect of 60 Hz magnetic fields on N-ethyl-N-nitrosourea induced neurogenic tumors in female F344 rats
  554. Evaluation of the potential promoting effect of 60 Hz magnetic fields onN-ethyl-N-nitrosourea induced neurogenic tumors in female F344 rats
  555. p53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation
  556. Interaction between Tobacco and Alcohol Consumption and the Risk of Cancers of the Upper Aero-Digestive Tract in Brazil
  557. Epidemiology of Acquisition and Clearance of Cervical Human Papillomavirus Infection in Women from a High‐Risk Area for Cervical Cancer
  558. Design and methods of the Ludwig-McGill longitudinal study of the natural history of human papillomavirus infection and cervical neoplasia in Brazil
  559. Assessing gains in diagnostic utility when human papillomavirus testing is used as an adjunct to Papanicolaou smear in the triage of women with cervical cytologic abnormalities
  560. Effect of Smoking Cessation and Tobacco Type on the Risk of Cancers of the Upper Aero-Digestive Tract in Brazil
  561. Human papillomavirus and prognoses of patients with cancers of the upper aerodigestive tract
  562. Human papillomavirus and prognoses of patients with cancers of the upper aerodigestive tract
  563. The influence of parental age on the risk of Wilms’ tumour
  564. Epidemiologic Evidence and Human Papillomavirus Infection as a Necessary Cause of Cervical Cancer
  565. Use of wood stoves and risk of cancers of the upper aero-digestive tract: a case-control study
  566. Clinical significance of histiocytes in the detection of endometrial adenocarcinoma and hyperplasia
  567. Relationship between dental factors and risk of upper aerodigestive tract cancer
  568. Preoperative irradiation therapy and radical hysterectomy: prognostic value of tumor regression after initial irradiation of squamous cell carcinoma of the cervix
  569. The role of professional diagnostic delays in the prognosis of upper aerodigestive tract carcinoma
  570. Predictors of professional diagnostic delays for upper aerodigestive tract carcinoma
  571. Erratum
  572. Assessing Harm Reduction Strategies: The Dilemma of Observational Studies
  573. Defining Safe Drinking Water
  574. The future of HPV testing in clinical laboratories and applied virology research
  575. Human papillomavirus infection in postmenopausal women with and without hormone therapy
  576. A prospective epidemiological study of gastrointestinal health effects due to the consumption of drinking water
  577. Use of Dipyrone during Pregnancy and Risk of Wilmsʼ Tumor
  578. Use of Dipyrone during Pregnancy and Risk of Wilmsʼ Tumor
  579. Conventional Cervical Cytologic Smears vs. ThinPrep Smears
  580. Family history of cancer is a risk factor for squamous cell carcinoma of the head and neck in Brazil: A case‐control study
  581. Transmission of Cervical Human Papillomavirus Infection by Sexual Activity: Differences between Low and High Oncogenic Risk Types
  582. Cancer Causes Revisited: Human Papillomavirus and Cervical Neoplasia
  583. Factors Influencing Regional Lymph Node Metastasis from Laryngeal Carcinoma
  584. Recent advances in the molecular epidemiology of cervical cancer
  585. The effect of cervical loop electrosurgical excision on subsequent pregnancy outcome: North American experience
  586. Parental Exposures to Pesticides and Risk of Wilms' Tumor in Brazil
  587. Associations between Cigarette Smoking and Each of 21 Types of Cancer: A Multi-Site Case-Control Study
  588. Maté, Coffee, and Tea Consumption and Risk of Cancers of the Upper Aerodigestive Tract in Southern Brazil
  589. Molecular Variant Analysis as an Epidemiological Tool to Study Persistence of Cervical Human Papillomavirus Infection
  590. Incidence of Norwalk virus infections during a prospective epidemiological study of drinking water related gastrointestinal illness
  591. A randomized clinical trial of single-dose versus fractionated-dose dactinomycin in the treatment of wilms' tumor. Results after extended follow-up
  592. ARE THE APPARENT EFFECTS OF CIGARETTE SMOKING ON LUNG AND BLADDER CANCERS DUE TO UNCONTROLLED CONFOUNDING BY OCCUPATIONAL EXPOSURES?
  593. Lateness of diagnosis of oral and oropharyngeal carcinoma: Factors related to the tumour, the patient and health professionals
  594. Association between timing of surgery during menstrual cycle and prognosis in pre-menopausal breast cancer
  595. Race and gender influences on the survival of patients with mouth cancer
  596. Multiple cancers of the upper aero-digestive tract: the challenge of risk factor identification
  597. Prognostic factors in laryngeal cancer patients submitted to surgical treatment
  598. Increased survival, limb preservation, and prognostic factors for osteosarcoma
  599. Epidemiological and clinical correlations with genetic characteristics of Wilms' tumor: Results of the Brazilian Wilms' tumor study group
  600. Single-doseversus fractionated-dose dactinomycin in the treatment of wilms' tumor. Preliminary results of a clinical trial
  601. A randomized trial to evaluate the risk of gastrointestinal disease due to consumption of drinking water meeting current microbiological standards.
  602. The Sexually Transmitted Disease Model for Cervical Cancer
  603. Presentation Risk factors for second cancers of the upper respiratory and digestive systems: A case-control study
  604. Response Design options for the study of second cancers
  605. Microcomputer-assisted multivariate survival data analysis using Cox's proportional hazards regression model
  606. Risk factors for oral cancer in Brazil: A case-control study
  607. Epidemiologic Correlates of Cervical Neoplasia and Risk of Human Papillomavirus Infection in Asymptomatic Women in Brazil
  608. Age and lateness of referral as determinants of extra-ocular retinoblastoma
  609. Microcomputer-assisted univariate survival data analysis using Kaplan-Meier life table estimators
  610. Factors of prognostic importance in childhood non-hodgkin's lymphoma treated with two modified lsa2-l2 protocols. A multivariate analysis approach
  611. Plasminogen activator expression and steroid hormone receptors in female breast cancer: A multifactorial study
  612. Correlation patterns of cancer relative frequencies with some socioeconomic and demographic indicators in Brazil: An ecologic study
  613. Catching up with history: Treatment of Wilms' tumor in a developing country
  614. Androgen, estrogen, and progesterone receptor levels in malignant and benign breast tumors: A multivariate analysis approach
  615. Sensitivity, specificity, and predictive value of laparoscopy for the staging of gastric cancer and for the detection of liver metastases
  616. SIMPLE ALGORITHMS FOR THE REPRESENTATION OF DETERMINISTIC AND STOCHASTIC VERSIONS OF THE REEDFROST EPIDEMIC MODEL USING A PROGRAMMABLE CALCULATOR
  617. Immunoserology of malaria
  618. An Oocyst-Transmitted Outbreak of Toxoplasmosis: Patterns of Immunoglobulin G and M over One Year
  619. A monoclonal antibody-based enzyme immunoassay to detect specificities in malarial antisera: a preliminary report
  620. Monoclonal Antibody Characterization of Plasmodium Falciparum Antigens
  621. Computer-assisted multiple categorization of absorbance values in ELISA through pictorial emulation of 96-well plates
  622. Diagnosis of Acute Acquired Toxoplasmosis with the Enzyme-Labelled Antigen Reversed Immunoassay for Immunoglobulin M Antibodies
  623. A Quantitative Method for Determining Toxoplasma gondii, White Cells, and the Volume of Ascitic Fluid in Experimentally Infected Mice
  624. Prospects
  625. Cervix
  626. Introduction
  627. Endometrium
  628. Epidemiology and the Role of Human Papillomaviruses
  629. Screening for Cervical Cancer Using HPV Tests
  630. Assessing Epidemiological Relations and the Role of Measurement Errors
  631. Evidence-Based Policy Recommendations on Screening and Prevention